CAN
VYNE icon

Cetera Advisor Networks’s VYNE Therapeutics VYNE Stock Holding History

Cetera Advisor Networks’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-6,389
Closed -$17.3K – 2679
2022
Q4 		$17.3K Hold
6,389
– – ﹤0.01% 2492
2022
Q3 		$26K Hold
6,389
– – ﹤0.01% 2042
2022
Q2 		$45K Buy
+6,389
New +$53.6K ﹤0.01% 2007
2020
Q3 		– Sell
-23
Closed -$3K – 2990
2020
Q2 		$3K Buy
+23
New +$3.12K ﹤0.01% 3172

Other funds holding VYNE

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Cetera Advisor Networks's VYNE Position: Q1 2023 in Review

Cetera Advisor Networks sold out of VYNE Therapeutics (VYNE) in Q1 2023, closing a stake of 6,389 shares — an estimated $17.3K sold.

Cetera Advisor Networks first reported a position in VYNE in Q2 2020 and held it in 4 quarters. The position peaked at $45K in Q2 2022. 23 funds tracked by Wall St. Rank hold VYNE as of Q1 2023.

  • Cetera Advisor Networks reported no remaining VYNE Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Cetera Advisor Networks sold 6,389 VYNE Therapeutics shares in Q1 2023, an estimated $17.3K.
  • Cetera Advisor Networks first reported a position in VYNE Therapeutics in Q2 2020 and held it in 4 quarters.
  • Cetera Advisor Networks's VYNE Therapeutics position peaked at $45K in Q2 2022.
  • 23 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2023.

Based on Cetera Advisor Networks's 13F filing for Q1 2023, filed 15 May 2023.